MIRA
HEALTHCAREMira Pharmaceuticals Inc
$1.00-0.02 (-1.96%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MIRA Today?
No stock-specific AI insight has been generated for MIRA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.90$2.45
$1.00
Fundamentals
Market Cap$42M
P/E Ratio—
EPS$-1.35
Dividend Yield—
Dividend / Share—
ROE-1.7%
Profit Margin—
Debt / Equity—
Trading
Volume102K
Avg Volume (10D)—
Shares Outstanding42.0M
MIRA News
20 articles- MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical StudiesYahoo Finance·Mar 23, 2026
- MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2Yahoo Finance·Mar 4, 2026
- Weekly Roundup on the Cannabis Sector & Psychedelic SectorYahoo Finance·Feb 8, 2026
- MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a StudyYahoo Finance·Feb 3, 2026
- Starfish Space Completes Autonomous Rendezvous and Proximity Mission in LEO with Impulse SpaceYahoo Finance·Dec 15, 2025
- Specialist Direct's ‘Mira’ Partners with dacadoo to Transform Recovery Management and Wellness OutcomesYahoo Finance·Oct 30, 2025
- MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a IndicationYahoo Finance·Oct 24, 2025
- Sector Update: Health Care Stocks Softer Late AfternoonYahoo Finance·Oct 16, 2025
- MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory PainYahoo Finance·Oct 16, 2025
- MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine AddictionYahoo Finance·Sep 30, 2025
- MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine AnalogYahoo Finance·Sep 22, 2025
- MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed AnimalsYahoo Finance·Sep 16, 2025
- MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking CessationYahoo Finance·Sep 12, 2025
- Mira Introduces Ultra4™, the First At-Home Hormone Monitor with Lab-Quality 4-in-1 TestingYahoo Finance·Aug 25, 2025
- MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose StageYahoo Finance·Aug 19, 2025
- MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or PregabalinYahoo Finance·Aug 12, 2025
- MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain StudyYahoo Finance·Jul 30, 2025
- MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic PainYahoo Finance·Jul 29, 2025
- MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for AcquisitionYahoo Finance·Jul 11, 2025
- Top Premarket GainersYahoo Finance·Jul 3, 2025
All 20 articles loaded
Price Data
Open$1.02
Previous Close$1.02
Day High$1.03
Day Low$1.01
52 Week High$2.45
52 Week Low$0.90
52-Week Range
$0.90$2.45
$1.00
Fundamentals
Market Cap$42M
P/E Ratio—
EPS$-1.35
Dividend Yield—
Dividend / Share—
ROE-1.7%
Profit Margin—
Debt / Equity—
Trading
Volume102K
Avg Volume (10D)—
Shares Outstanding42.0M
About Mira Pharmaceuticals Inc
MIRA Pharmaceuticals, Inc. is a clinical development stage biopharmaceutical company. The company is headquartered in Baltimore, Maryland.
HEALTHCAREDRUG MANUFACTURERS - GENERAL
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - GENERAL
CIK—
Composite FIGI—
Share Class FIGI—